The Asia Pacific self-sampling blood collection and storage devices market is witnessing strong momentum, driven by the rapid transformation of healthcare delivery models and increasing patient preference for home-based diagnostic solutions. Valued at US$ 20.5 Mn in 2022, the market is projected to expand at a CAGR of 10.0% from 2023 to 2031, reaching approximately US$ 48.1 Mn by 2031. This robust growth reflects the region’s shift toward preventive healthcare, digital health integration, and decentralized diagnostic systems.

Market Overview

Self-sampling blood collection and storage devices allow individuals to collect blood samples at home or in non-clinical settings without requiring direct assistance from healthcare professionals. These samples are then stored or sent to laboratories for diagnostic analysis. The growing demand for convenient, cost-effective, and minimally invasive testing methods is reshaping traditional blood collection practices across Asia Pacific.

The adoption of these devices has gained significant traction due to advancements in microsampling technologies, dried blood spot systems, and volumetric absorptive microsampling tools. Integration with mobile health applications and telemedicine platforms has further improved usability and accessibility, enabling real-time health monitoring and faster diagnostic turnaround.

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85686

Key Market Drivers

Rising Prevalence of Chronic and Blood-Related Disorders

One of the strongest growth drivers for the Asia Pacific market is the increasing burden of chronic and blood-related diseases. Conditions such as anemia, hemophilia, leukemia, lymphoma, and infectious diseases like hepatitis B and C are highly prevalent across the region.

Anemia, particularly iron-deficiency anemia, affects a large population of women and children in Southeast Asia. Similarly, chronic HBV and HCV infections remain significant public health concerns, with global elimination targets set by international health agencies. These conditions require frequent monitoring, which makes self-sampling devices a practical solution for long-term disease management.

Blood cancers and clotting disorders also contribute to rising diagnostic demand. Early detection and continuous monitoring using at-home sampling solutions are improving patient outcomes and reducing pressure on healthcare systems.

Post-COVID-19 Acceleration of Home Diagnostics

The COVID-19 pandemic fundamentally changed healthcare delivery across Asia Pacific. Hospitals and diagnostic centers faced unprecedented pressure, leading to a rapid shift toward remote testing and telehealth services. Self-sampling blood collection devices emerged as a safe alternative to traditional in-clinic blood draws.

Techniques such as Volumetric Absorptive Microsampling (VAMS) and Dried Blood Spot (DBS) collection became widely adopted for infectious disease screening, including HIV, hepatitis, and COVID-19 antibody testing. This shift has continued even after the pandemic, with patients and healthcare providers increasingly favoring decentralized diagnostic models.

Technological Advancements and Digital Integration

Technological innovation is another key growth factor. Modern self-sampling devices now integrate with smartphones, cloud platforms, and wearable technologies, allowing users to track, store, and share health data seamlessly.

These advancements have improved accuracy, reduced sample contamination risks, and enhanced patient compliance. As digital healthcare ecosystems expand across countries like China, Japan, Singapore, and India, the demand for connected diagnostic tools is expected to rise significantly.

Market Segmentation Insights

By Product Type

The collection devices segment dominates the market and is expected to maintain its leadership throughout the forecast period. These devices are designed for easy finger-prick or capillary blood collection, offering convenience and minimal discomfort. Their widespread adoption in both clinical trials and home diagnostics is a major factor driving segment growth.

By Application

The health & wellness segment holds the largest share of the market. Increasing consumer awareness about preventive healthcare and self-monitoring is fueling demand for at-home diagnostic tools. These devices are widely used for tracking cholesterol levels, glucose levels, hormone balance, and general wellness indicators.

Other key application areas include disease management, drug discovery, epidemiological studies, and clinical research, where self-sampling helps reduce logistical complexity and costs.

By Customer Base

The home settings segment is expected to dominate due to rising preference for personalized healthcare. Consumers increasingly value privacy, convenience, and time efficiency, making at-home testing solutions highly attractive. Academic institutions and research organizations also represent important end users, particularly for large-scale population health studies.

Country-Level Analysis

China, including Hong Kong and Mainland China, is expected to lead the Asia Pacific market. The country’s strong healthcare infrastructure, government support for preventive care, and growing adoption of self-testing technologies are key growth drivers. Additionally, China’s established medical device manufacturing ecosystem supports large-scale production and export.

Singapore is another high-growth market, driven by advanced healthcare systems and early adoption of digital health solutions. Strong regulatory frameworks and innovation-friendly policies are accelerating the deployment of self-sampling technologies in clinical and research settings.

Competitive Landscape

The Asia Pacific self-sampling blood collection and storage devices market is moderately consolidated, with several global and regional players actively investing in innovation and expansion. Key companies include:

• Tasso Inc.
• Trajan Group Holdings Limited
• Cardinal Health, Inc.
• LAMEDITECH
• Prenetics Global Limited
• Capitainer
• Drawbridge Health
• Seventh Sense Biosystems
• LifeCell International Pvt. Ltd.
• Hebei Xinle Science & Technology Co., Ltd.

These companies are focusing on R&D investments, strategic partnerships, and product innovation to strengthen their market position. The emphasis is on developing user-friendly, accurate, and minimally invasive blood collection technologies suitable for home and clinical applications.

Recent Developments

Recent industry developments highlight the sector’s rapid evolution:

• Tasso Inc. received MDSAP certification, enabling regulatory compliance across multiple international markets.
• Capitainer partnered with AstraZeneca to advance patient-centric dried blood sampling technologies in clinical trials.
• Drawbridge Health secured approval for its OneDraw Blood Collection Device in Japan, expanding its Asia Pacific footprint.
• Trajan Group Holdings Limited acquired Neoteryx, strengthening its microsampling portfolio and global presence.

Conclusion

The Asia Pacific self-sampling blood collection and storage devices market is entering a phase of accelerated growth, supported by rising chronic disease prevalence, post-pandemic behavioral shifts, and continuous technological innovation. As healthcare systems increasingly move toward decentralization and patient-centric care models, self-sampling solutions are expected to become an integral part of future diagnostic ecosystems.

With strong government support, expanding digital health infrastructure, and active participation from key industry players, the market is well-positioned for sustained expansion through 2031.

Source: https://www.transparencymarketresearch.com/asia-pacific-self-sampling-blood-collection-and-storage-devices-market.html